Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Depreciation and Depletion (2016 - 2023)

Tg Therapeutics (TGTX) has 8 years of Depreciation and Depletion data on record, last reported at $73000.0 in Q3 2023.

  • For Q3 2023, Depreciation and Depletion fell 3.95% year-over-year to $73000.0; the TTM value through Sep 2023 reached $246000.0, down 20.65%, while the annual FY2022 figure was $303000.0, 7.45% up from the prior year.
  • Depreciation and Depletion reached $73000.0 in Q3 2023 per TGTX's latest filing, up from $32000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $80000.0 in Q4 2021 and bottomed at $23000.0 in Q1 2019.
  • Average Depreciation and Depletion over 5 years is $53473.7, with a median of $59000.0 recorded in 2021.
  • Peak YoY movement for Depreciation and Depletion: surged 97.06% in 2021, then plummeted 58.97% in 2023.
  • A 5-year view of Depreciation and Depletion shows it stood at $28000.0 in 2019, then soared by 89.29% to $53000.0 in 2020, then skyrocketed by 50.94% to $80000.0 in 2021, then fell by 8.75% to $73000.0 in 2022, then changed by 0.0% to $73000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Depreciation and Depletion were $73000.0 in Q3 2023, $32000.0 in Q2 2023, and $68000.0 in Q1 2023.